Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II abemaciclib monotherapy in biomarker-selected recurrent/metastatic head and neck cancer
2016-004537-25Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in head and neck cancer (HNC), sponsored by Centre Léon Bérard. Primary endpoint: 8-week non-progression rate. Started Sep 2017; status: completed.
02
Drugs
abemaciclib
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2016-004537-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004537-25.